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(57) ABSTRACT
Embodiments of the invention include capsules for contain-
ing medical implants and delivery systems for release of
active biological substances into a host body. Delivery
systems comprise a capsule comprising an interior enclosed
by walls, and a source of active biological substances
enclosed within the capsule interior, wherein the active
biological substances are free to diffuse across the capsule
walls. The capsule walls comprise a continuous mesh of
biocompatible fibers and a seal region where two capsule
walls overlap. The interior of the capsule is substantially
isolated from the medium surrounding the capsule, except
for diffusion of at least one species of molecule between the
capsule interior and the ambient medium, and prevents cell
migration into or out of the capsule. Methods for preparing
and using the capsules and delivery systems are provided.
11 Claims, 10 Drawing Sheets
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BIOCOMPATIBLE CAPSULES AND
METHODS OF MAKING
CROSS REFERENCE TO RELATED
APPLICATIONS
This application claims priority from U.S. Provisional
Application Ser. No. 61/662,870, filed Oct. 5, 2011, entitled
"Method for Formation and Manufacture of Carbon Nano-
tube Mesh Bucky Paper Capsules for Transplantation of
Cells and Tissue and Implantation of Medical Devices"
which is incorporated by reference herein in its entirety.
ORIGIN OF THE INVENTION
The invention described herein was made by an employee
of the United States Government and may be manufactured
and used by or for the Government of the United States of
America for governmental purposes without the payment of
any royalties thereon or therefor.
FIELD OF THE INVENTION
One or more embodiments of the present invention relate
to medical devices and methods of medical treatment of
disease. Other pertinent fields of the invention include drug
delivery systems, transplant medicine, cell therapeutics and
synthetic biology.
BACKGROUND
Transplantation of cells and tissues from one human to
another is limited by the host immune system, which iden-
tifies and rejects non-host cells and tissues with high effi-
ciency. One strategy for avoiding or surmounting this barrier
is to enclose the cells in a "cage" that provides a biological
shield (an "immune shield") that prevents the transplanted
cells and tissues from being rejected by the host immune
system. This strategy has application in endocrinology (e.g.,
islet cell transplantation), gene therapy (transplantation of
cells to provide a missing protein or to replace a dysfunc-
tional protein), immune therapy, or other biological therapy
(transplantation of cells to provide specific active biological
molecules, such as immunoglobulins, cytokines, immune
regulators or biological response modifiers). Such a system
could also provide a micro-environment, within a human or
other host body, for tissue engineering, to allow for differ-
entiation of cells or assembly of tissue structures with
two-dimensional or three-dimensional architecture, or the
formation of nascent organs, for subsequent use in the host
or elsewhere.
Immune shielding may also serve as an important strategy
for preventing immune rejection of implantable medical
devices that range in size from ultra-small scale nanopar-
ticles and nanoprobes to large scale macroscopic devices.
The strategy of immune shielding allows use of a wider
range of materials in the construction of implantable medical
devices than would otherwise be possible because of the
presence of the host immune system and therefore the
potential for unwanted immune system responses.
Many materials have been proposed as immune shields,
including specially treated biological and non-biological
materials, silicon, ceramics, synthetic polymers and other
non-organic materials. As a rule, these foreign materials tend
to provoke an immune response in the host body, which has
limited development in this field. Another phenomenon
associated with transplantation of foreign materials into a
N
host is localized scar formation ("fibrotic capsule forma-
tion") and/or obstruction of pores in the foreign material.
The presence of pores is required in most biological appli-
cations for efficient transfer of nutrients, gases and other
5 biological factors into the interior of the cage, and efficient
transfer of waste products, metabolites and secreted sub-
stances from inside the capsule to outside the cage.
What is needed is a biocompatible material that can be
formed into a "cage" or similar structure for containing cells
io or tissue that prevents or limits access by the host immune
system to the foreign cells or tissue. The capsule material
should allow the cells and/or tissue to be maintained in a live
and functioning state; and in some cases, should permit the
cells and/or tissue to carry out normal (physiological) or
15 specially engineered sensing functions and/or normal
(physiological) or specially engineered secretory functions.
The capsule material itself should not provoke (or should
limit significantly) an immune response in the host system.
The capsule material itself should not elicit (or should limit
20 significantly) scar formation in the host that, together with
an immune response, could lead to obstruction of the pores
of the capsule material. The capsule material itself should
resist protein deposition that, together with scar formation or
an immune response, could lead to obstruction of the pores.
25 Preferably, the material should be flexible and sufficiently
resilient to withstand the forces that may be involved in
surgical implantation or transplantation and other forces that
may be present in the host environment. The material should
be configurable into a variety of geometric shapes, to
30 optimize transport of substances across the capsule and to
promote the maintenance of cells and/or tissues.
U.S. Pat. No. 7,070,923 to Loftus describes the use of
carbon nanotube Bucky paper for the transplantation or
implantation of cells and/or tissues or medical devices,
35 wherein containers for cells and/or tissues or medical
devices are fabricated from multiple layers of flat pieces of
carbon nanotube Bucky paper in a sandwich configuration.
Three-dimensional structures made from flat pieces of car-
bon nanotube Bucky paper, such as tubes made by rolling up
40 flat pieces of carbon nanotube Bucky paper, or rolls of
Bucky paper with multiple spiral layers are also disclosed.
However, the formation of 3-dimensional structures from
flat pieces of Bucky paper requires potentially time-consum-
ing and potentially labor intensive procedures to manipulate
45 the flat pieces of Bucky paper. The formation of 3-dimen-
sional structures from flat pieces of Bucky paper also
requires seams between individual pieces of Bucky paper,
either "edge to edge" seams or "overlapping seams," and, in
some cases, the use of additional materials such as suture or
50 other ligature to close the seams. These seams may be
undesirable, because they may constitute points or regions
of structural weakness of the Bucky paper containers, which
could result in rupture of the Bucky paper containers. In
addition, the seams are undesirable because they may result
55 in leakage or migration of the cells and/or tissue or medical
devices from inside the Bucky paper containers to outside
the Bucky paper containers. In addition, the seams may
serve as points of entry of host immune system cells to the
interior of the Bucky paper containers, which could result in
6o an undesirable immune system response to the cells and/or
tissues or medical devices contained therein.
U.S. Pat. No. 7,618,647 to Weber describes uses of Bucky
paper on medical implants such as stents. The Bucky paper
is applied by wrapping the stents with Bucky paper and
65 securing the paper with clamps, sewing or glue. Nonplanar
Bucky paper can allegedly be formed using a cylindrical or
tubular filter, or by forming a filter into a pouch shape.
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Weber states that an implant can be placed inside the pouch
and additional Bucky paper formed on top to enclose the
implant. However, no method of forming Bucky paper on
top of a pouch containing an implant is provided, and the
methods otherwise disclosed for forming Bucky paper in
situ would not be operable to close the top of a pouch in a
leak-proof manner. Spraying techniques are also described
where a suspension of nanotubes is sprayed onto an implant,
the solvent dried and the nanotubes compressed onto the
implant; however spraying, drying and compressing would
damage the structure of the finished capsule, disrupting its
integrity. Weber fails to disclose any means of creating a
leak-proof capsule or enclosure for any device or bioactive
structure or material.
SUMMARY OF THE INVENTION
Embodiments of the invention include capsules for con-
taining medical implants and delivery systems for release of
active biological substances into a host body. Delivery
systems comprise a capsule comprising an interior enclosed
by walls, and a source of active biological substances
enclosed within the capsule interior. The capsule walls
comprise a continuous mesh of biocompatible fibers and a
seal region where two capsule walls overlap. The interior of
the capsule is substantially isolated from the medium sur-
rounding the capsule, except for diffusion of at least one
species of molecule between the capsule interior and the
ambient medium. The seal region where the capsule walls
overlap comprises a mesh which is sufficiently continuous to
prevent cell migration into or out of the capsule.
In some embodiments, the source of active biological
substances is a plurality of cells, wherein the plurality of
cells releases the one or more active biological substances
such that the one or more active biological substances are
free to diffuse across the capsule walls.
In some embodiments, the source of active biological
substances is a composition comprising one or more active
biological substances, wherein the composition releases the
one or more active biological substances such that the one or
more active biological substances are free to diffuse across
the capsule walls, i.e., from inside the capsule to outside of
the capsule. The composition can be a sustained release
composition.
In some embodiments, the source of active biological
substances is a medical device providing the controlled
release of one or more active biological substances, wherein
the composition releases the one or more active biological
substances such that the one or more active biological
substances are free to diffuse across the capsule walls.
The biocompatible fibers can comprise carbon nanotubes
(single-walled nanotubes or multi-walled nanotubes), car-
bon fibers, carbon nanofibers, graphene, graphene flakes,
graphene fragments, graphene fibers, or polysaccharides
(e.g., bacterial cellulose). The fibers can be randomly ori-
ented or substantially oriented in the capsule walls. The
capsule can comprise fibers of varying composition in one or
more distinct layers in the capsule walls. The capsules can
incorporate beads into one or more distinct layers in the
capsule walls. The capsule can further comprise fibers or
beads disposed in the interior of the capsule. The capsule
walls have a thickness in a range of 1-100 µm and an area
density in a range of 420-1500 µgm/cm2.
In some embodiments, medical devices encapsulated by a
capsule are provided, wherein the capsule encapsulates the
medical device such that the medical device does not
provoke a response from the host immune system when
4
implanted into a host body. The capsule comprises biocom-
patible fibers and forms an interior enclosed by walls. The
interior of the capsule is substantially isolated from the
medium surrounding the capsule, except for diffusion of at
5 least one species of molecule between the capsule interior
and the ambient medium.
In some embodiments, methods are provided for prepar-
ing a biocompatible capsule. The methods can comprise
providing a perforated mold, immersing the perforated mold
io into a suspension of biocompatible fibers in a suspending
medium, withdrawing the suspending medium through the
perforated mold such that the fibers form a tangled mesh
around the outside of and conform to the shape of the
perforated mold, and removing the perforated mold to
15 produce a biocompatible capsule component, and sealing the
capsule. The sealing comprises forming at least one region
of overlap where two regions of capsule wall are in intimate
contact, and pressing the two regions of capsule wall
together such that the capsule wall surfaces are bound by van
20 der Waals forces and/or entanglement of the biocompatible
fibers. When sealed, the capsule interior is substantially
isolated from the medium surrounding the capsule, except
for diffusion of at least one species of molecule between the
capsule interior and the ambient medium.
25 The methods can further comprise providing a plurality of
molds to prepare a plurality of capsule components, and
assembling the plurality of capsule components to form an
enclosed 3-dimensional capsule. The suspending medium
can be withdrawn by applying positive pressure to the
30 outside of the perforated mold or by applying negative
pressure to inside of the perforated mold.
The methods can further comprise inserting a plurality of
cells into the capsule before assembling the capsule com-
ponents together. The methods can further comprise insert-
35 ing a medical device into the capsule before assembling the
capsule components together.
The methods can further comprise inserting a source of
one or more active biological substances into the capsule
before assembling the capsule components together. The
4o active biological substance can include pharmaceutically
active agents, chemotherapeutic agents, radio-labeled
agents, peptides, proteins, growth factors, cytokines, growth
inhibitors, polynucleotides, and the like, without limitation.
In some embodiments, the source of active biological
45 substances is a plurality of cells, wherein the plurality of
cells releases the one or more active biological substances
such that the one or more active biological substances are
free to diffuse across the capsule walls.
In some embodiments, the source of active biological
50 substances is a composition comprising one or more active
biological substances, wherein the composition releases the
one or more active biological substances such that the one or
more active biological substances are free to diffuse across
the capsule walls. The composition can be a sustained
55 release composition.
In some embodiments, the source of active biological
substances is a medical device providing the controlled
release of one or more active biological substances, wherein
the composition releases the one or more active biological
60 substances such that the one or more active biological
substances are free to diffuse across the capsule walls.
The biocompatible fibers can comprise carbon nanotubes,
carbon fibers, carbon nanofibers, graphene, graphene flakes,
graphene fragments, graphene fibers, or polysaccharides
65 (e.g., bacterial cellulose). The methods can further comprise
orienting the fibers as the capsule components are formed.
The methods can further comprise incorporating different
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fibers into one or more distinct layers as the capsule com-
ponents are formed. The methods can further comprise
incorporating beads into one or more distinct layers as the
capsule components are formed. The methods can further
comprise incorporating fibers into the interior of the capsule
components to form an interior scaffold before sealing the
capsule. The methods can further comprise incorporating
beads into the interior of the capsule before sealing the
capsule.
In some embodiments, delivery systems for release of
active biological substances are provided comprising a
source of active biological substances enclosed within a
capsule made according to methods disclosed herein.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 illustrates an embodiment of a capsule containing
islet cells.
FIG. 2 illustrates one embodiment of a delivery system.
FIG. 3 illustrates an embodiment of a mold for forming a
capsule.
FIG. 4 illustrates one embodiment of the sequence of
events in the preparation of capsules.
FIG. 5 illustrates one embodiment of the sequence of
events in the preparation of capsules.
FIG. 6 illustrates one embodiment of the sequence of
events in the preparation of capsules incorporating beads.
FIG. 7 illustrates one embodiment of the sequence of
events in the preparation of capsules.
FIG. 8 illustrates one step in the sequence of events in the
preparation of capsules.
FIG. 9 illustrates one step in the sequence of events in the
preparation of capsules.
FIG. 10 shows a scanning electron micrograph of a
cylindrical capsule after manufacture.
DETAILED DESCRIPTION OF THE
INVENTION
Before the present invention is described in detail, it is to
be understood that unless otherwise indicated this invention
is not limited to specific materials, polymers or devices. It is
also to be understood that the terminology used herein is for
the purpose of describing particular embodiments only and
is not intended to limit the scope of the present invention.
It must be noted that as used herein and in the claims, the
singular forms "a," "and" and "the" include plural referents
unless the context clearly dictates otherwise. Thus, for
example, reference to "a polymer" includes two or more
polymers, and so forth.
Where a range of values is provided, it is understood that
each intervening value, to the tenth of the unit of the lower
limit unless the context clearly dictates otherwise, between
the upper and lower limit of that range, and any other stated
or intervening value in that stated range, is encompassed
within the invention. The upper and lower limits of these
smaller ranges may independently be included in the smaller
ranges, and are also encompassed within the invention,
subject to any specifically excluded limit in the stated range.
Where the stated range includes one or both of the limits,
ranges excluding either or both of those included limits are
also included in the invention. Where the modifier "about'
is used, it is understood that the stated quantity may vary by
up to ±10%.
I. Definitions and Overview
As used herein, the term "active biological substance" (or
"ABS") refers to molecules that bind to receptors or act as
6
pharmacologically active agents and affect some property of
biological tissues, without limitation. An ABS can include
hormones, peptides or proteins (enzymes, ligands, cytok-
ines, transcription factors, etc.), pharmaceutical agents, anti-
s bodies, polynucleotides (interfering RNAs, DNA), prohor-
mones, or precursors to ABS that become activated in the
host body, and the like without limitation. An ABS also
includes labeled substances, such as fluorescent labels, spin
labels, radioactive labels, and so forth. An ABS also includes
io drug-ABS conjugates of drugs or cytotoxic agents (e.g.,
maytansine, etc.) or fusion protein-ABS constructs.
As used herein the term "ambient medium" refers to the
environment surrounding a capsule. When implanted into a
host body, the ambient medium can include blood, intersti-
15 tial fluids and extracellular matrix, and the like.
As used herein, the term "beads" refers to beads,
microparticles, or nanoparticles typically spherical or near
so.
As used herein, the term "biocompatible" refers to the
20 property of being relatively inert with respect to provoking
a response from a host immune system.
As used herein, the term "capsule" refers to a container
comprising biocompatible fibers and enclosing a 3-dimen-
sional volume which is sealed by van der Waals interactions
25 and/or entanglement of the biocompatible fibers of surfaces
in intimate contact. The biocompatible fibers interact and
bond without glue, stitching, clamps or other closing tech-
niques.
As used herein, the term carbon nanotube ("CNT")
30 encompasses both single wall nanotubes or multiwalled
nanotubes.
As used herein, the term ` Bucky paper" refers to a mesh
prepared from CNTs. The preparation and use of Bucky
paper is described in U.S. Pat. Nos. 7,070,923 and 7,135,172
35 to Loftus, incorporated by reference herein.
As used herein, the term "substantially isolated" refers to
the property of preventing the passage of cells across the
walls of the capsule, while allowing the passage of at least
one species of molecule between the capsule interior and the
4o ambient medium.
Embodiments of the present invention utilize methods for
creating 3-dimensional containers or capsules made of a
biocompatible fibrous mesh. The novel methods improve
upon the methods and constructs prepared using the methods
45 described in U.S. Pat. Nos. 7,070,923 and 7,135,172 to
Loftus. Advantageously, the methods do not rely on manipu-
lation of flat pieces of Bucky paper, and do not require
stitching to assemble into a sealed container. The improved
methods provide for more efficient manufacture of contain-
50 ers, largely eliminate the requirement for seams between
individual pieces of Bucky paper, and increase the range of
possible shapes of the Bucky paper containers. In addition,
the methods make it possible to control the orientation of the
individual CNTs of the meshwork to tailor the meshwork
55 properties to specific applications, as well as to incorporate
other components into the container structure during the
manufacturing process.
Compared to both the Loftus patents cited above and U.S.
Pat. No. 7,618,647 to Weber, embodiments of the invention
60 provide new methods of sealing capsules and similar enclo-
sures without using any material other than the biocompat-
ible fibers from which the walls of the capsules are made.
The sealing is provided both to protect the contents placed
in the enclosure from attack by the host immune system and
65 to prevent the contents from leaking out into the host. In one
aspect, a method is provided for creating fibrous mesh from
suspensions of CNTs or other biocompatible fibers to form
US 9,770,405 B1
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three-dimensional structures, such as hollow tubes, cylin-
ders closed at one end, as well as more complex shapes, for
the purpose of providing containers for cells and/or tissues
or medical devices, for the purpose of transplanting or
implanting the cells and/or tissues into a host. The methods 5
can also provide containers for medical devices to be
implanted into a host.
The capsules formed from CNTs and carbon nanofibers
are biocompatible and nonthrombogenic, and can conceiv-
ably be placed into contact with blood, i.e., in a blood vessel, 10
if suitably sized. The biocompatibility of the capsule mate-
rial (CNT meshwork) was demonstrated in a rabbit model.
A flat portion of a capsule wall (CNT meshwork) was
prepared by the vacuum filtration method and sterilized by
gamma irradiation. The portion was implanted into the 15
sub-retinal space of an albino rabbit. After 1 week, the
implant site showed no signs of acute inflammation, by
direct observation.
Some embodiments incorporate beads which can be used
with externally applied radiation to trigger or otherwise 20
signal the capsules. Some embodiments include CNTs or
other filaments inserted into the interior of the capsule.
Methods for achieving preferential orientation of the CNTs
(or other filaments) within the capsule wall, as well as the
use of a variety of CNT lengths or filament lengths are also 25
described.
II. Delivery Systems and Capsules
Embodiments of the present invention provide capsules 30
for containing medical implants and delivery systems for
release of active biological substances into a host body. The
delivery systems comprise a capsule comprising an interior
enclosed by walls, and a source of active biological sub-
stances enclosed within the capsule interior. The capsule 35
walls comprise a continuous mesh of biocompatible fibers
and a seal region where two capsule walls overlap. Sealing
of the capsule is achieved by van der Waals interaction
and/or entanglement of the biocompatible fibers of surfaces
in intimate contact. The biocompatible fibers interact and 40
bond without glue, stitching, clamps or other closing tech-
niques. Discontinuity can exist where the walls overlap, but
interdigitation of fibers occurs which results in a mesh which
is sufficiently continuous to prevent cell migration from the
capsule to the ambient medium or from the ambient medium 45
into the capsule.
The interior of the capsule is substantially isolated from
the medium surrounding the capsule, except for diffusion of
at least one species of molecule between the capsule interior
and the ambient medium. Where the capsule is used for 50
growth, differentiation, non-differentiation or transplanta-
tion of cells and/or tissue, the capsule porosity can be
selected to allow passage of some molecules and to exclude
passage of other molecules. Where the capsule is used for
containing cells and/or tissue, the capsule walls preferably 55
have a selected porosity that permits exchange of one or
more selected molecules between the capsule interior and
exterior, such as 02, CO2, amino acids, glucose, peptides
and small proteins.
The capsule may also be used for secretion of one or more 60
active biological substances ("ABS") at one or more con-
trolled rates, from the capsule interior to the capsule exterior,
thereby providing a delivery system for the one or more
ABS. In some embodiments, the source of active biological
substances is a plurality of cells, wherein the plurality of 65
cells releases the one or more active biological substances
such that the one or more active biological substances are
8
free to diffuse across the capsule walls. In some embodi-
ments, the source of active biological substances is a com-
position comprising one or more active biological sub-
stances, wherein the composition releases the one or more
active biological substances such that the one or more active
biological substances are free to diffuse across the capsule
walls. The composition can be a sustained release compo-
sition. In some embodiments, the source of active biological
substances is a medical device providing the controlled
release of one or more active biological substances, wherein
the composition releases the one or more active biological
substances such that the one or more active biological
substances are free to diffuse across the capsule walls.
As an example, where the patient has a non-functioning or
poorly functioning pancreas or thyroid, a substitute tissue,
organ fragments or cells from another human, or even from
another species, may be enclosed in the capsule which acts
as an immune shield within the patient's body. The capsule
protects the non-self cells and/or tissue from an immune
reaction by the patient's body but allows secretion of the
desired ABS (e.g., insulin or thyroid hormone) into the
patient's body adjacent to the location of the capsule. The
rate at which the ABS is secreted into the patient's body is
determined by the intrinsic sensing function of the cells
and/or tissue (e.g., for insulin secreting cells and/or tissue,
sensing the concentration of glucose) and is not limited by
the capsule, if the capsule is sufficiently porous.
One embodiment of an insulin delivery system 100 is
illustrated in FIG. 1 (shown schematically in cross-section).
A capsule containing islet cells is prepared and implanted in
a patient needing treatment for diabetes. The islet cells are
viable and nourished by the patient's body. Immune cells
(shown labeled as "Killer T-cell") and islet cells cannot
penetrate the capsule walls. The islet cells are not in contact
with the host immune system and therefore do not generate
and/or are protected from the host immune response. How-
ever, small molecules such as glucose, insulin, CO2 and 02
are able to diffuse across the capsule walls.
Similarly, additional delivery systems can be envisaged,
such as thyroid tissue for delivery of thyroid hormone,
genetically engineered cells for delivery of specific proteins
such as clotting factors, cytokines, antibodies, without limi-
tation.
A capsule can also support implantation into a host body
of a biological insert that is a plurality of cells genetically
engineered to possess a specialized function. The activity
associated with this function is controlled by an agent that
can regulate specific gene expression or other specific bio-
logical activity in the biological insert and thus provide the
specialized function. For some applications, the biological
insert is implanted with the specialized function turned off
(inactive). This insert is maintained in the host body in a live
state until the specialized function is needed, at which point
the biological insert is activated, for example, by adminis-
tration of a chemical or biological triggering agent. When
the specialized function is no longer needed, a second
triggering agent is administered to deactivate the insert or
expression of the specific gene or specific biological activity
of the insert. Alternatively, a third triggering agent can be
administered to trigger death or its equivalent in the bio-
logical insert. This approach may have particular usefulness
in providing medical care to military personnel or to astro-
nauts on long space flights, where access to conventional
medical care is limited.
In some embodiments, the capsule can be used as a
delivery system to provide release of an ABS into a host
body by placing the ABS directly into the capsule (i.e.,
US 9,770,405 B1
9
without using cells and/or tissue to secrete the ABS). The
ABS can be provided in solution or as a solid. The ABS can
be provided in a sustained release composition, providing
release of the ABS into the capsule for an extended period
of time. For example, the sustained release composition can
provide a sustained release of an ABS from a capsule for a
year or more.
Where an ABS is passively released from a capsule, one
concern is the inevitable decrease in rate of release as the
concentration of the ABS within the capsule decreases. This
decrease in rate can be controlled, although not eliminated,
by enclosing a second capsule 212 of theABS, with a second
initial ABS concentration cjt-0), within a first, larger
capsule 200 of the active biological substance, having an
initial ABS concentration c jt-0), which is in turn immersed
in an ambient medium, having a relatively unvarying ABS
concentration colt-0), as illustrated in FIG. 2. Preferably, the
concentration values satisfy co(t=0)<<c,(t-0)<<cz(t=0). The
rate constants for diffusion of the ABS from the first capsule
to the second capsule, and from the second capsule to the
first capsule, have the respective values k12 and k2,, where
these two values may be equal or unequal. The rate constants
for diffusion of the ABS from the first capsule to the
ambient-medium, and from the ambient medium to the first
capsule, have the respective values k,, and k,,, where these
two values may be equal or unequal. Preferably, k,,<k,,.
The capsule material for the first capsule can be formed from
CNT fibers or another material that serves as an immune
shield; the capsule material for the second capsule may be an
immune shield material or another suitable material that may
not provide immune shielding. By suitable choices of ratios
of the parameters, the rate of decrease of the resulting
secretion rate k,,-c,(t) from the first capsule to the ambient
medium is reduced relative to the rate of decrease that would
occur if the first capsule, but not the second capsule, is
present. The rate of decrease of the resulting passive release,
k,,-c,(t), from the first capsule to the ambient medium may
be further reduced by provision of N capsule, numbered
n=1, ... , N (N>-3), with capsule number n being larger than
and enclosing capsule number n+1 (n=1, ... , N-1). This
approach may be used for a capsule or for a first capsule
made of any other material that serves as an immune shield.
A stand-alone first capsule 200 can also be used for secre-
tion, if the decrease in passive release rate for the active
biological substance ABS from the pocket is not a great
concern, or if the ABS is poorly soluble and hence can
maintain a relatively constant dissolution profile with time.
A capsule may also be used to sense the presence or
monitor the concentration of one or more selected sub-
stances in an ambient medium surrounding part or all of the
capsule. In this situation, the capsule walls are modified, as
appropriate, to allow or promote transfer of the substance
across the capsule wall, from the ambient medium to the
capsule interior. A chemical substance or device, which
reacts and undergoes a chemical or physical reaction, is
located within the capsule interior. The presence or intensity
of this resulting reaction within the capsule is monitored to
determine the presence or the concentration of the substance
in the ambient medium. For example, a glucose sensing
device can be enclosed within a capsule and implanted in a
host body. The glucose sensing device can monitor the
interstitial fluids surrounding the capsule for the concentra-
tion of glucose, and a signal can be transmitted out of the
host body to a receiver for recording the information.
Similar applications to other sensing functions will imme-
diately be understood by those skilled in the art.
10
A capsule can also enclose a mechanical, electromechani-
cal, electronic or physical medical device and provide pro-
tection from the host immune system. There is no particular
size limit to the capsules that can be formed, and the
5 capsules can be sized large enough to enclose miniaturized
medical devices such as osmotic pumps for drug delivery
(e.g., ALZETO Osmotic Pumps) or larger medical devices
such as pacemakers or microfluidic delivery systems. In
addition, the capsule can be formed as a long thin tube for
io containing a medical device having a long and thin shape,
for example, catheters and guidewires. The capsule provides
the added advantage of being nonthrombogenic and so
provides protection against clot formation upon exposure of
the host body to the medical device.
15 The medical device may provide or transform a selected
chemical or a selected chemical signal, optical signal, elec-
tronic signal, electromagnetic signal, ultrasound signal,
mechanical signal or other signal within the capsule, for
subsequent use inside or outside the capsule, and may be a
20 nano-device (with a device diameter of the order of mano-
meters to microns) or may be a larger device, referred to here
as a macroscopic device. The capsule material may prevent
passage of selected molecular substance(s) and may permit
passage of other selected molecular substances, but does not
25 interfere directly with operation of the medical device. One
or more selected chemical, optical, electronic, electromag-
netic, ultrasound or mechanical signals can be generated
externally and passed through the capsule material to acti-
vate, deactivate, control or otherwise change the status of the
30 medical device within the cage. Apart from replacement of
mis-functioning or non-functioning medical devices and
their respective cages from time to time, no further actions
are required, other than passage of the selected signal, or
sequence of signals, through the capsule material.
35 Activation of the biological insert can be implemented,
for example, using one or more optical or other suitable
signals to "awaken" the specialized function of the insert.
The optical signal may have one or more wavelengths in the
visible, infrared or microwave regions, depending upon the
4o distance of the capsule from an exposed portion of the host
body through which the optical signal enters. A timed
sequence of non-simultaneous optical signals can be used to
raise the energy level of a particular electron or group of
electrons to a selected level(s) at which activation occurs. An
45 ultraviolet optical signal can be used for such purpose, if the
capsule is located close to an exposed surface of the body,
for example, in a skin layer. Until such activation occurs, the
biological insert within the capsule is effectively inert.
Delivery of one or more selected optical signals can also be
50 used to deactivate an already-active biological insert so that
the biological insert can be switched on and off, depending
upon need.
Transfer characteristics across a meshwork of CNT mate-
rial or cell adhesion interactions with the capsule walls can
55 also be modified by inclusion and/or attachment of selected
functional groups (e.g., groups involving H, O, N, S, F, Cl,
Br, I, a protein, a peptide, a polypeptide, a growth factor, a
cytokine, a nucleic acid and/or a nucleic acid polymer) to the
CNTs before the capsule is prepared. Some of these func-
60 tional groups may serve as "markers" in a manner similar to
biological markers on a cell membrane, thereby selectively
controlling the chemical substances that are transferred
across a capsule wall and/or the rate at which such transfer
occurs.
65 The modification can also include adsorption or covalent
attachment of specific growth factors, cytokines, antibodies,
extracellular matrix proteins or the like. For example, the
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modification can include covalent attachment of CNTF,
polylysine, collagen, fibronectin, laminin, brain-derived
neurotrophic factor, ciliary neurotrophic factor, nerve
growth factor, forskolin, or inhibitors of myelin-associated
glycoprotein and inhibitors of NOGO). If necessary, the 5
adsorption of specific growth factors, cytokines, antibodies,
extracellular matrix proteins to the capsule can be stabilized
by partial or complete cross-linking of these specific growth
factors, cytokines, antibodies, extracellular matrix proteins
to one another, rather than by direct binding to the CNT io
elements of the capsule.
In one approach, the capsules can be prepared from crude
preparations of single wall carbon nanotubes ("SWCNTs")
synthesized by a laser ablation technique, available from
commercial sources. Other preparations of SWCNTs or 15
multiple wall carbon nanotubes ("MWCNTs"), such as those
synthesized by the well known HiPCO technique (a high
pressure process using carbon monoxide) are also accept-
able. The crude preparation is first purified by refluxing in
nitric acid for 160 hours and the resulting product is cen- 20
trifuged, and the pellet is suspended in potassium hydroxide
solution (pH-10), then washed twice by centrifugation and
re-suspension. The purified CNTs are washed twice in
distilled water, using centrifugation and resuspension. The
purified CNTs are re-suspended in a suspending medium 25
(e.g., distilled water, or other solvent). The suspended CNTs
can be mechanically formed into Bucky paper by removal of
water by vacuum filtration over a cellulose filter or similar
filter. The suspended CNTs can also be used with the
perforated molds as described herein to form 3-dimensional 30
capsules.
Portions of the CNTs incorporated in the capsule pro-
duced here may be "bundled", or partially or fully aligned,
due to liquid flow through the mesh of CNTs, which may
provide a higher than normal density of CNTs in an array. 35
The biocompatible fibers can comprise CNTs, carbon fibers,
carbon nanofibers, graphene, graphene flakes, graphene
fragments, graphene fibers, or polysaccharides (e.g., bacte-
rial cellulose). The fibers can be randomly oriented or
preferentially oriented in the capsule walls. The capsule can 40
comprise fibers of varying composition in one or more
distinct layers in the capsule walls. The capsules can incor-
porate beads into one or more distinct layers in the capsule
walls. The capsule can further comprise fibers or beads
disposed in the interior of the capsule. The capsule walls 45
have a thickness in a range of 1-100 µm and an area density
in a range of 420-1500 µgm/cm2.
Bucky paper or capsules as described herein can be
prepared having an area density of CNTs in the range of
420-1500 µgm/cm2. As shown in inset 101 in FIG. 1, 50
scanning electron microscopy imaging of a portion of the
capsule after fabrication demonstrates the fibrous character
of the capsule wall. Individual meshwork elements are
bundles of carbon nanotubes, and the assembly of fibers into
a mesh provides a pore size of approximately 20-1000 11111. 55
Generally, the size can be selected such that cells cannot pass
through the pores but the ABS of interest passes freely.
Separate procedures can be utilized for generating and
controlling patterns or densities of growth of an array of
SWCNTs or MWNTs. Fibers can be grown to a length 60
between about 1µm and 200 µm, or longer if desired. The
length of the fiber can be chosen to provide desired char-
acteristics to the final structure provided. For example,
longer fibers may become more entangled to provide a
stronger structure, if such is desired. Conversely, shorter 65
fibers may result in a capsule that could be more easily
disrupted, if such is desired. During the preparation of the
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capsule, the fibers form a mesh or mat. The mesh thickness
h (mesh) and mesh density partly determine the capsule
porosity. A mesh density range of 4x106-6x1010 cm2 corre-
sponding to a range d=40 mu-5 µm for average nearest
neighbor center-to-center separation distance can be pro-
duced where a substrate is not used for CNT growth. Use of
a higher average thickness h may require use of a higher
separation distance d, to preserve similar Bucky paper
behavior.
Capsules suitable for implantation can comprise nano-
tubes, fibers or other filaments in the interior of the capsule,
not just as part of the capsule wall. In some embodiments,
it may be desirable for CNTs, carbon nanofibers or other
filamentous materials to be placed into the interior of the
capsule, in order to serve as support scaffolding for the cells
and/or tissues that are placed into the scaffold. Including
fibers in the capsule interior may promote the growth of
cells, influence the differentiation state of cells, or control
the 3-dimensional arrangement of the cells within the inte-
rior of the capsule.
Capsules can be manufactured with different preparations
of CNTs, including CNTs of different lengths, including
ultrashort CNTs. Various fiber lengths can also be used to
prepare capsules made from carbon nanofibers and other
types of filaments.
Capsules can be formed using a plurality of layers,
including one or more layers with different types of fila-
ments or fibers, different filament orientation, incorporating
different beads, etc. Embodiments of the invention include a
wide range of possible filament types in addition to CNTs
that could be used to make porous meshwork capsules, to
provide a broader range of capsule types and more options
for manufacture.
III. Fibers
Capsules can be made of carbon nanotubes, carbon fibers,
carbon nanofibers, graphene, graphene flakes, graphene
fragments, graphene fibers, or polysaccharide fibers (e.g.,
bacterial cellulose), or any other filamentous, largely inert
material. Many of these materials are well known in the art.
For example, the preparation of single wall CNTs is
described in U.S. Pat. No. 7,105,596 to Smalley. One
advantage of carbon nanofibers and carbon fibers such as
those made from CNTs is the relative biological inertness of
the material, resulting in biocompatible surfaces which do
not provoke immune response from the host immune sys-
tem.
The fibers can be modified to covalently attach biologi-
cally active molecules to provide specific surface reactivity
when implanted in the host. For example, CNTs or carbon
nanofibers can be treated with acid to open the end of the
nanotube, resulting in generation of a reactive carboxylic
acid moiety (COON). The COOH reacts with amines on a
desired protein to produce an amide bond, covalently bond-
ing the CNT and protein together. In this way, the CNT can
be derivatized or labeled with a desired amine-containing
substance (usually a protein).
In addition, as the CNTs are generally staggered in length
as they assemble into bundles, the modified ends will also be
staggered along the length of a bundle of CNTs. The
modified fibers can then present a variety of protein signal-
ing molecules to the host, which may affect the host
response to the capsule. For example, the fibers can be
modified with inhibitors of T-cells, neutrophils, fibroblasts,
macrophages, etc., in order to prevent formation of a fibrous
capsule by the host body and thereby prolong the operating
US 9,770,405 B1
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life of the delivery system or capsule. The fibers can be
modified with additional biomolecules such as growth fac-
tors and inhibitors as described above.
IV. Beads
The capsules can incorporate beads in the capsule mate-
rial or in the capsule interior. "Beads" may include beads,
microparticles or nanoparticles, and any or all of these
materials can be incorporated into the capsule wall, and
beads, microparticles or nanoparticles can be placed into the
capsule interior, along with other contents, to impart desired
properties to the capsule wall, or to promote desired char-
acteristics of the capsule contents. Beads are typically
formed of polymers such as polystyrene or latex, and can be
functionalized with biomolecules such as inhibitors or
growth factors, as described above. A wide variety of beads
are commercially available, and the linkage chemistries for
functionalizing the beads are well known in the art. The
beads to be incorporated into the capsule wall can be in the
range of 100 mu to 5 microns in size so that the beads are
retained within the capsule wall.
Beads, microparticles, nanoparticles or other structures
entrapped in the capsule wall, or otherwise incorporated into
the capsule wall, can be used to facilitate triggering of
capsules by externally applied signals, in order that external
signals can be delivered to the capsule and received by the
capsules to trigger (turn on or turn off) or regulate the
capsule wall or its contents, in order to control the func-
tioning of the capsule or its contents, or to cause disinte-
gration of the capsule, or to otherwise render some perma-
nent change to the capsule, to cause it to shut down or to
release its contents. Signals may include microwave signals;
other E/M radiation, particle radiation, such as proton radia-
tion or heavy ion radiation, and ultrasound signals.
Embodiments of the invention make possible the incor-
poration of a wide range of beads to augment the function-
ality of the carbon meshwork capsules. The incorporation of
beads could be accomplished by entangling beads in the
fiber meshwork during manufacture of the capsule, sand-
wiching beads between layers of the fiber meshwork during
manufacture of the capsule, or covalently or noncovalently
attaching beads to the CNTs or other mesh elements. The
incorporation of beads into the structure of the capsule takes
advantage of a growing range of bead and particle types that
could easily be incorporated into the capsule.
Beads, microparticles or nanoparticles can be designed to
be sensitive to radiation, including electromagnetic radiation
(including visible light, UV light, X-rays, gamma rays, IR
waves, microwaves, etc.) or particle radiation (protons,
heavier elements) or magnetic fields, so that an external
"signal" could be delivered to the capsules, once implanted
into the body to trigger the capsule, to turn on, turn off, or
otherwise regulate the action of the contents of the capsule,
or to regulate the properties of the capsule wall, or even to
cause destruction (e.g., loss of integrity) of the capsule or its
contents, if such was desired. The advantage is that the
capsules containing cells, tissues or medical devices can be
made to operate autonomously, by being sensitive to exter-
nal signals that would trigger appropriate events inside the
capsule; or, signaling/triggering could be used to tailor the
functioning of the capsule contents deliberately, to respond
to changing circumstances of the host (recipient) or to
changing circumstances of the host environment.
In some embodiments, the beads can comprise radio-
opaque markers such as metals. The use of radio-opaque
substances in beads can provide a means for localizing or
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visualizing a capsule after it is implanted within a host.
Metals that are useful for localizing a capsule preferably
include nonferrous metals that are compatible with com-
puted tomography or magnetic resonance imaging in a
5 patient. Typical metals would include gold or titanium.
In some embodiments, the beads can comprise radioactive
substances that emit ionizing radiation. The ionizing radia-
tion can be used as a marker for the location of the capsule.
Alternatively, or in addition, the ionizing radiation can be
10 used as a treatment protocol for disease, for example, for
localized treatment of cancer or other growth. For localizing
a capsule or for local treatment, typically the radioactive
substance includes gamma emitting radionuclides and
would be secured within the capsule so that it does not
15 diffuse out of the capsule and penetrate throughout the
patient's body.
V. Methods of Preparing Capsules
20 The methods provide an efficient and practical way to
form biocompatible fibrous capsules in the form of a 3-di-
mensional CNT meshwork, to serve as containers for cells
and/or tissues, to serve as containers for medical devices, or
to serve as repositories of other active substances. The
25 methods can facilitate the implantation of these cells, active
substances or medical devices into a host recipient. The use
of CNT meshwork for these applications serves generally to
provide a shield or barrier between the transplanted/im-
planted items, such that the host immune system cannot
30 interact with the contents within the CNT meshwork con-
tainer. Without the "immune shield," the host immune
system could trigger an undesirable immune response (in-
cluding but not limited to a rejection response, or an acute
or chronic inflammatory reaction) directed against the trans-
35 planted/implanted items.
The methods can comprise providing a perforated mold,
immersing the perforated mold into a suspension of bio-
compatible fibers in a suspending medium, withdrawing the
suspending medium through the perforated mold such that
40 the fibers form a tangled mesh around the outside and
conform to the shape of the perforated mold, and removing
the perforated mold to produce a biocompatible capsule
component, and sealing the capsule. The sealing comprises
forming at least one region of overlap where two regions of
45 capsule wall are in intimate contact, and pressing the two
regions of capsule wall together such that the capsule wall
surfaces are bound by van der Waals forces and/or entangle-
ment of the biocompatible fibers. When sealed, the capsule
interior is substantially isolated from the medium surround-
50 ing the capsule, except for diffusion of at least one species
of molecule between the capsule interior and the ambient
medium.
The methods can further comprise providing a plurality of
molds to prepare a plurality of capsule components, and
55 assembling the plurality of capsule components to form an
enclosed 3-dimensional capsule. Withdrawing the suspend-
ing medium can be provided by applying positive pressure
to the outside of the perforated mold or by applying negative
pressure to inside of the perforated mold.
60 The methods can further comprise inserting a plurality of
cells into the capsule before assembling the capsule com-
ponents together. The methods can further comprise insert-
ing a medical device into the capsule before assembling the
capsule components together.
65 The methods can further comprise inserting a source of
one or more active biological substances into the capsule
before assembling the capsule components together. The
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active biological substance can include pharmaceutically
active agents, chemotherapeutic agents, radio-labeled active
agents, peptides, proteins, growth factors, cytokines, growth
inhibitors, polynucleotides, and the like, without limitation.
In some embodiments, the source of active biological 5
substances is a plurality of cells, wherein the plurality of
cells releases the one or more active biological substances
such that the one or more active biological substances are
free to diffuse across the capsule walls.
In some embodiments, the source of active biological io
substances is a composition comprising one or more active
biological substances, wherein the composition releases the
one or more active biological substances such that the one or
more active biological substances are free to diffuse across
the capsule walls. The composition can be a sustained 15
release composition.
In some embodiments, the source of active biological
substances is a medical device providing the controlled
release of one or more active biological substances, wherein
the composition releases the one or more active biological 20
substances such that the one or more active biological
substances are free to diffuse across the capsule walls.
The biocompatible fibers can comprise carbon nanotubes,
carbon fibers, carbon nanofibers, graphene, graphene flakes,
graphene fragments, graphene fibers, or polysaccharides 25
(e.g., bacterial cellulose). The methods can further comprise
orienting the fibers as the capsule components are formed.
The methods can further comprise incorporating different
fibers into one or more distinct layers as the capsule com-
ponents are formed. The methods can further comprise 30
incorporating beads into one or more distinct layers as the
capsule components are formed. The methods can further
comprise incorporating fibers into the interior of the capsule
components to form an interior scaffold before sealing the
capsule. The methods can further comprise incorporating 35
beads into the interior of the capsule before sealing the
capsule.
Embodiments of the invention include methods for cre-
ating 3-dimensional containers (capsules) made of biocom-
patible fibers by use of a perforated mold. The shape and 40
dimensions of the mold determine the shape and dimensions
of the capsule. The molds can be generally tubular in form,
made of a rigid material, with perforations (holes or pores),
and are designed to be immersed into a suspension of
biocompatible fibers (e.g., carbon nanotubes, "CNTs") dis- 45
persed in a suspending medium such as a solvent (e.g.,
acetone) or other liquid such as water with added surfactant.
The perforations provide a way to remove the solvent from
a suspension of fibers, such that the fibers are deposited onto
the surface of the mold, forming a meshwork with an overall 50
3-dimensional shape that is determined by the 3-dimensional
shape of the mold. For example, a cylindrical mold 300 with
a round bottom can be used to form a cylindrical container
with a round bottom (as shown in the FIG. 3). The perfo-
rations 302 in the rigid mold permit fluid or liquid to pass 55
from the exterior to the interior of the mold, but are sized to
prevent fibers (e.g., CNTs or bundles of CNTs) from passing
through the perforations.
As shown in FIG. 4, the perforated mold 400 is placed
into a suspension of CNTs (panel A) and the mold is secured 60
to a vacuum source (not shown). The suspending medium is
withdrawn by applying a vacuum to the inside of the
cylindrical mold, so that suspending medium is drawn
through the mold, carrying CNTs to the surface of the mold
(panel B). The perforations of the mold are sized to prevent 65
passage of the CNTs into the interior of the mold, so that that
the CNTs accumulate at the surface of the mold, where they
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become entangled with each other to form a meshwork. With
continued application of a vacuum to the interior of the
mold, more and more of the suspending medium is with-
drawn, resulting in increasing deposition of CNTs to the
outside of the mold, resulting in increasing thickness of the
CNT 404 meshwork (panel Q. Additional CNTs and/or
suspending medium can be added to the suspension as
desired to continue the process.
In another embodiment, instead of using a vacuum to
draw the suspending medium through the perforations of the
mold, pressure can be applied to the exterior to the mold, and
the interior of the mold left at atmospheric pressure (FIG. 5).
With this variation, the difference in pressure between the
interior of the mold and the exterior of the mold can be
greater than with use of vacuum, which can be used to speed
the rate at which suspension fluid is forced through the
perforations (holes or pores) of the mold.
In some embodiments, beads can be added to the fiber
meshwork during the manufacturing process. Beads 606 can
be added to the suspension of fibers 604, so that as the fluid
phase is drawn into the interior of the perforated mold (e.g.,
by vacuum or pressure), the beads become entrapped in the
growing meshwork (shown schematically in FIG. 6). Alter-
natively, the beads can be added to the suspension after a
layer of CNTs is deposited, resulting in the incorporation of
a layer of beads after the first layer of CNTs is formed, so
that the beads are not exposed to the interior of the resulting
CNT meshwork capsule. The layer of beads can then be
covered by depositing another layer of CNT or other fiber
meshwork if desired.
Different beads with different functionalities can be incor-
porated into one or more separate layers of the container, if
desired. The use of layered construction can be used to
position some beads closer to the interior of the resulting
capsule, and some beads closer to the exterior, where distinct
functionalities of the interior versus the exterior of the
capsule are desired. Modified CNTs can also be incorporated
into one or more layers of the capsule during the manufac-
turing process.
A scaffold of fibers (e.g., CNTs, carbon fibers or graphene
fibers) can also be placed into the interior of the capsule, to
serve as a support for the growth of cells, typically after the
capsule has been formed. The fibers are suspended in solvent
or aqueous solution with surfactant in a concentration range
of one microgram per ml to 100 mg per ml (a higher
concentration than that used to form the capsule). The
suspension is added to the capsule interior and as the solvent
or surfactant is removed, the fibers form bundles that create
a scaffold of fibers crossing the interior of the capsule. The
advantage is that cell or tissue growth in the capsule could
be enhanced or optimized, so that more efficient biological
effects can be achieved once implantation takes place,
including longer useful lifespan of the contents of the
capsule, or more reliable functioning of the contents of the
capsule. For use as a scaffold for growth of cells or support
of implanted tissue, the fibers in the interior of the capsule
are provided typically at less than one percent of the interior
volume of the capsule.
Various techniques can be used to influence or control the
orientation of the CNTs, nanofibers or filaments in the
manufacture of the capsules. For example, the mold can be
rotated or moved vertically with respect to the CNT sus-
pension during the deposition process. The use of directed
flow, or stirring of the suspension can also affect the orien-
tation of the fibers in the final capsule. The rotation of the
mold is depicted schematically in FIG. 7. It can be seen that
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the majority of the CNTs are generally oriented with the
direction of rotation rather than exhibiting a random distri-
bution of orientations.
After the capsule formation is complete, the mold 800 can
be removed, leaving behind the CNT meshwork 804, still
holding the shape of the mold, as shown in FIG. 8. The
capsule can be dried to remove suspending medium and
stored prior to use.
In one embodiment, two capsule portions can be created
where the outside diameter of one capsule portion is
approximately equal to the inside diameter of the other
capsule portion, and a "complete" capsule is formed by
taking the two capsule portions and joining them together by
inserting the open end of the smaller capsule portion into the
open end of the larger capsule portion, overlapping the open
ends. For example, two capsule "halves" 904 and 905 can be
formed and assembled by inserting the open end of one half
capsule into the other to form a closed capsule 908. This
embodiment is shown schematically in FIG. 9. The capsule
is sealed by non-covalent association between capsule
halves (the CNTs are attracted to one another by van der
Waals forces), and entanglement of fibers at the mating
capsule portion surfaces to hold the complete capsule
together. The two portions of capsule can have the same or
different shapes and dimensions, so long as the overlapping
portions come into close contact.
Other methods of sealing the capsules will be readily
apparent to those of skill in the art. For example, the capsule
having one open end as depicted in FIG. 8 could be sealed
shut by pinching the top portion closed, or contacting the
open end with some other capsule of suitable shape, or
contacting it with a suitable shape and thickness of Bucky
paper. The CNTs can non-covalently associate and entangle
to close the capsule. Any method of closing the capsule can
be used so long as the fiber entanglement is preserved.
The finished capsule demonstrates a smooth, uniform
surface of CNT meshwork, as shown using low power
scanning electron micrograph (FIG. 10). The width of the
cylinder shown in FIG. 10 is approximately 1.5 mm.
In another embodiment, the mold can have an oval
cross-section and no perforations in the end cap. A tube with
an oval cross-section can be formed on the mold and then
removed from the mold. The aspect ratio of the oval
dimension can be from about 2:1 to about 20:1 (a circular
shape has an aspect ratio of 1:1). In these embodiments, a
capsule can be formed by pressing the ends together along
a length to seal the ends of the tube. Typically the seal length
can be at least equal to the long axis of the oval. No
additional fastening aids such as glue, stitching, or clamps
are required, and only a single molded component is
required to form an enclosed and sealed container. Instead,
the ends of the capsule can be pinched together to seal the
two capsule wall surfaces together. Under conditions of
close proximity, the wall surfaces are attracted due to the van
der Waals forces between the CNTs. Sealing can also be
effected by placing the walls in proximity while contacting
the walls with aqueous solution, whereby the CNT ends are
able to entangle with the CNT ends from the adjacent wall
without being damaged (changing density or porosity).
For example, an oval tube having an aspect ratio of 5:1
has been used with good result. Depending on the particular
choice of fibers, wall thickness, and fiber density, the fin-
ished capsule wall will have a limiting flexibility. Actions
which try to bend the wall material past a limiting strain
point will cause fiber breakage that can affect the integrity of
the capsule wall. Typical example tubes made at an aspect
ratio of 5:1 can be sealed by pressing the ends together
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without significant fiber breakage, and good end seals hav-
ing no measureable leakage of cells from a capsule interior
can reliably be made. To optimize entanglement, it is gen-
erally desirable to avoid sheer forces which can break fibers.
5 The two surfaces should be pressed firmly together in a
manner which does not cause the mating surfaces to slide
relative to each other.
VI. Advantages and Applications
10
The capsules utilize materials that have not yet been used
extensively in biological applications. These materials pro-
vide biocompatibility and the potential to permit or block the
passage of various substances across the capsule by con-
15 trolling the porosity of the capsule wall. These materials also
provide an ease of use and wide variety of shapes into which
the material can be shaped, and an ability to control the
dimensions of a capsule made from the material. The
capsules provide a micro-environment in which cells can
20 grow, cell differentiation can be promoted or suppressed and
cells and tissues can be transplanted. In addition, secretion,
sensing and monitoring of chemical substances present can
be performed, without the need for, or with limited need for,
use of immunosuppressive drugs or other special precau-
25 tions.
Because the 3-dimensional structures are not assembled
from flat pieces of pre-formed Bucky paper, fewer seams are
required, and therefore there is less chance that the contain-
ers could leak or rupture or otherwise fail to keep the
30 contents fully shielded from the host immune system and
other host factors that could damage the contents, or allow
the contents to escape from the containers.
The method of manufacture of these 3-dimensional struc-
tures by use of a perforated mold provides potentially more
35 variation in the range of shapes of the CNT meshwork
structures.
No suture or other ligature material is needed to create a
fully closed container, which simplifies the process of pre-
paring and loading the containers, and potentially minimizes
40 the chance of an immune reaction that could be caused by
the suture or ligature, specifically, because the suture or
ligature may not be as biocompatible as the carbon nantube
meshwork. The elimination of non-carbon closure materials
(that could cause an unwanted host immune response after
45 implantation into the body) can improve the biocompatibil-
ity of the capsule.
The methods can be scaled up to provide for large-scale
production of these 3-dimensional CNT meshwork struc-
tures, for efficient manufacture, with minimal manual inter-
50 vention compared to manufacture of containers built up
from flat pieces of Bucky paper.
Nanotube, filament or fiber orientation can be controlled,
to optimize the physical properties of the capsule and
optimize the pore size or pore size distribution, providing
55 more precise control of the properties of the capsule. The
advantage is more precise control of the properties of the
capsule.
The manufacturing methods provide for efficient means
for controlling the orientation of the CNT meshwork struc-
60 tural elements (single-walled CNTs, multi-walled CNTs, or
bundles of single-walled or multi-walled CNTs), for
example, by varying the alignment of fibers, which may
impart advantageous structural and/or mechanical charac-
teristics to the CNT meshwork structures.
65 The manufacturing methods make possible the formation
of CNT meshwork structures comprised of multiple layers,
where layers with different properties may be desirable. For
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example, an inner layer may be selected or modified to have
certain properties to optimize the interaction of the contents
of the container with this layer, and an outer layer may be
selected or modified to optimize the interaction of this layer
with the surrounding tissue, medium or cells.
The manufacturing methods make possible the incorpo-
ration of beads into the CNT meshwork capsule, where the
beads may be used to impart some added functionality to the
CNT meshwork. The beads may be confined to the space
between distinct layers of CNT meshwork, and different
types of beads with different functionalities may be used,
each confined to its own layer.
It is to be understood that while the invention has been
described in conjunction with the preferred specific embodi-
ments thereof, that the description above as well as the
examples that follow are intended to illustrate and not limit
the scope of the invention. The practice of the present
invention will employ, unless otherwise indicated, conven-
tional techniques of organic chemistry, pharmaceutical
chemistry, immunochemistry, biochemistry and the like,
which are within the skill of the art. Other aspects, advan-
tages and modifications within the scope of the invention
will be apparent to those skilled in the art to which the
invention pertains. Such techniques are explained fully in
the literature.
All patents, patent applications, and publications men-
tioned herein, both supra and infra, are hereby incorporated
by reference in their entireties for all purposes.
EXAMPLES
Example 1
Islet Cells Encapsulated in a Capsule for Treatment
of Diabetes
A capsule is prepared in two complementary halves from
CNTs having dimensions of approximately 1 mm by 10 mm.
Islet cells (harvested from donors) are added to one half of
the capsule in an amount of from about 106 to about 10'
cells, along with solution containing appropriate growth
medium, and the capsule is assembled by inserting the
complementary capsule half. The capsule is implanted in a
patient under the skin. The cells within the capsule are
nourished by the extracellular fluids of the patient's body,
and can respond to glucose which diffuses across the pores
of the capsule. The islet cells produce insulin in response to
elevated glucose, which diffuses out of the capsule across
the pores, and into the blood stream of the patient, thereby
providing a supplemental source of insulin for controlling
blood glucose levels. Because the islet cells automatically
respond to elevated glucose and cease to generate insulin
when glucose levels fall, the capsule provides an in situ
insulin delivery system capable of controlling blood glucose
in a patient in need thereof.
Example 2
Acute Response Treatment of Radiation Exposure
A capsule is prepared in two complementary halves from
CNTs having dimensions of approximately 1 mm by 10 mm.
Cells (prokaryotic or eukaryotic, obtained from cultures of
cells or harvested from donor animals) are genetically
engineered to produce granulocyte colony stimulating factor
(G-CSF) and can respond to a trigger such as an antibiotic
resistance gene engineered into the cells to release G-CSF,
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or can respond to the radiation exposure itself. When acute
radiation exposure has occurred, the trigger (e.g., antibiotic)
can be administered, thereby causing the cells in the capsule
to produce and release G-CSF. The cells are added to one
5 half of the capsule in an amount of from about 106 to about
10' cells, along with solution containing appropriate growth
medium, and the capsule is assembled by inserting the
complementary capsule half. The capsule is implanted in a
10 
patient under the skin. The cells within the capsule are
nourished by the extracellular fluids of the patient's body,
and respond to the trigger to release G-CSF, which diffuses
across the pores of the capsule. The G-CSF diffuses into the
blood stream of the patient, thereby providing a supplemen-
15 tal source of G-CSF for controlling levels of blood cells.
Because the cells respond to the trigger and cease to generate
G-CSF when levels of the trigger molecule fall, the capsule
provides an in situ G-CSF delivery system capable of
stimulating blood cell growth and replenishment in a patient
20 suffering from acute radiation exposure.
Example 3
Cells Encapsulated in a Capsule for Gene Therapy
25
A capsule is prepared in two complementary halves from
CNTs having dimensions of approximately 1 mm by 10 mm.
Cells (prokaryotic or eukaryotic, obtained from cultures of
cells or harvested from donor animals) genetically engi-
30 neered to produce factor VIII or IX are added to one half of
the capsule in an amount of from about 106 to about 10'
cells, along with solution containing appropriate growth
medium, and the capsule is assembled by inserting the
35 complementary capsule half. The capsule is implanted in a
patient under the skin. The cells within the capsule are
nourished by the extracellular fluids of the patient's body,
and produce clotting factors which diffuse across the pores
of the capsule. The cells produce clotting factors at a
40 constant rate, which diffuse out of the capsule across the
pores, and into the blood stream of the patient, thereby
providing a supplemental source of clotting factors for
controlling blood clotting. The capsule provides an in situ
delivery system capable of controlling blood clotting in a
45 patient in need thereof.
Example 4
Antibody Producing Cells Encapsulated in a
50 Capsule for Treatment of Cancer
A capsule is prepared in two complementary halves from
CNTs having dimensions of approximately 1 mm by 10 mm.
Cells (prokaryotic or eukaryotic, obtained from cultures of
55 cells or harvested from donor animals) genetically engi-
neered to produce anti-tumor antibodies are added to one
half of the capsule in an amount of from about 104 to about
10$ cells, along with solution containing appropriate growth
medium, and the capsule is assembled by inserting the
60 complementary capsule half. The capsule is implanted in a
patient near the site of a tumor. The cells within the capsule
are nourished by the extracellular fluids of the patient's
body, and produce antibodies which diffuse across the pores
of the capsule. The cells produce antibodies at continuously,
65 which diffuse out of the capsule across the pores, into the
vicinity of the tumor in the patient, thereby providing a
localized source of anti-tumor antibodies for treating cancer.
US 9,770,405 B1
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The capsule provides an in situ delivery system capable of
providing antibodies in a patient in need thereof.
Example 5
Chemotherapeutic Agents Encapsulated in a
Capsule for Treatment of Cancer
A capsule is prepared in two complementary halves from
CNTs having dimensions of approximately 1 mm by 10 mm.
A sustained release composition comprising an anthracy-
cline, or cytosine arabinoside, or a combination thereof, is
inserted into one half capsule, and the capsule is assembled
by inserting the complementary capsule half. The capsule is
implanted in a patient near the site of a tumor. The sustained
release composition provides chemotherapeutic agents that
diffuse across the pores of the capsule. The chemotherapeu-
tic agent(s) diffuse out of the capsule across the pores, and
into the vicinity of the tumor in the patient, thereby provid-
ing a high localized concentration of chemotherapeutic
agents to treat the cancer. The capsule provides an in situ
delivery system capable of providing localized delivery of
chemotherapeutic agents in a patient in need thereof.
What is claimed is:
1. A method for preparing a biocompatible capsule com-
prising:
providing a perforated mold,
immersing the perforated mold into a suspension of
biocompatible fibers in a suspending medium,
withdrawing the suspending medium through the perfo-
rated mold such that the fibers form a tangled mesh
around the outside of the perforated mold and conform-
ing to the shape of the perforated mold,
removing the perforated mold to produce a first biocom-
patible capsule component,
producing a second biocompatible capsule component,
sealing the first and second biocompatible capsule com-
ponents to form the capsule;
wherein the sealing comprises
forming at least one region of overlap between the first
and second capsule components where the fibers of
the at least one overlap region are in intimate contact,
pressing the at least one overlap region together such
that the fibers of the at least one overlap region are
bound by van der Waals forces, and
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forming a smooth, uniform surface of fibers along the
exterior surface of the capsule, and
wherein the interior of the capsule is substantially isolated
from the medium surrounding the capsule, except for
5 diffusion of at least one species of molecule between
the capsule interior and the ambient medium.
2. The method of claim 1, wherein the withdrawing is
provided by at least one of applying positive pressure to the
outside of the perforated mold and applying negative pres-
to sure to the inside of the perforated mold.
3. The method of claim 1, further comprising providing a
plurality of perforated molds to form a plurality of fibrous
capsule components, and assembling the plurality of fibrous
15 capsule components together to form an enclosed 3-dimen-
sional capsule, wherein two fibrous capsule components are
of different diameters such that an open end of the capsule
component with a smaller diameter is inserted into an open
end of the capsule with a larger diameter to form an overlap
20 region where the fibers are attracted to one another by van
der Waals forces.
4. The method of claim 1, further comprising inserting a
plurality of cells into the capsule before sealing the capsule.
5. The method of claim 1, further comprising inserting a
25 medical device into the capsule before sealing the capsule.
6. The method of claim 1, wherein the biocompatible
fibers include at least one of carbon nanotubes, carbon
fibers, carbon nanofibers, graphene, graphene flakes, gra-
phene fragments, graphene fibers, and polysaccharides.
30 7. The method of claim 1, further comprising orienting the
fibers as the capsule is formed.
8. The method of claim 1, further comprising incorporat-
ing different fibers into one or more distinct layers as the
35 capsule is formed.
9. The method of claim 1, further comprising incorporat-
ing beads into one or more distinct layers of the fibers as the
capsule is formed.
10. The method of claim 1, further comprising incorpo-
40 
rating fibers into the interior of the capsule to form an
interior scaffold before sealing the capsule.
11. The method of claim 1, further comprising incorpo-
rating beads into the interior of the capsule before sealing the
capsule.
